Notícias

Coronavirus disease 2019 (COVID-19), which emerged as a major public health threat, has affected >400 million people globally leading to...

Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are useful for patients’ treatment of the coronavirus disease...

The pandemic coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently the most formidable...

Coronavirus disease 2019 (COVID-19) is associated with excess mortality after hospital discharge. Identification of patients at increased risk of death...

The identification of the Omicron (B.1.1.529.1 or BA.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in...

Grupos de Trabalho encerram discussões sobre os temas específicos a serem trabalhados e entram na segunda fase das atividades para...

The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in...

A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome...

Effective treatments for COVID-19 are urgently needed, but conducting randomized trials during the pandemic has been challenging.

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic is currently the major challenge to global public health. Two proteases,...

Coronaviruses, including the recent pandemic strain SARS-Cov-2, use a multifunctional 2′-O-methyltransferase (2′-O-MTase) to restrict the host defense mechanism and to...

A ABIFINA passa a integrar grupo de trabalho da Anvisa, que sob a coordenação da Gerência de Inspeção e Fiscalização...